Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome
about
Timing of therapies for Down syndrome: the sooner, the betterWnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behaviorFluoxetine induces input-specific hippocampal dendritic spine remodeling along the septotemporal axis in adulthood and middle age.Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected].Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndromeHypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis.Aerosol-induced brucellosis increases TLR-2 expression and increased complexity in the microanatomy of astroglia in rhesus macaquesChanging Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.The GABAergic Hypothesis for Cognitive Disabilities in Down SyndromeEarly neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.Down syndrome and the complexity of genome dosage imbalance.Rodent models in Down syndrome research: impact and future opportunities.Cognitive performance of juvenile monkeys after chronic fluoxetine treatment.Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.A third copy of the Down syndrome cell adhesion molecule (Dscam) causes synaptic and locomotor dysfunction in Drosophila.In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T.
P2860
Q26779297-1232F6FB-C027-4122-A4D2-18F2832F75B4Q27008843-2E599A0D-C759-400C-98D7-CBD3C657D534Q30667140-DED3269F-614C-49AD-9B9F-026075C95EDAQ33659830-A16E52C9-EDA1-491C-AD0F-2306CA75A3A4Q33711022-034A9BB3-E9A7-48C2-BC5B-9AF7D2AEBC00Q34714277-E3759067-27B9-4996-89A5-4E838CF2FC44Q35187108-B1E98BCC-2E8D-4C34-94F6-5273C686B4FDQ36621106-CE9206A6-2BD9-4C84-8F8A-921B548C3580Q36637693-C5E195E3-70BD-4AB4-9486-7F80FFF6E8D7Q37352486-4F7F5BBC-B839-4181-A826-F2BD20555486Q37415153-AD56439F-B934-4205-B8D8-37E32E60D055Q37683060-3580D2BB-EA24-4CDE-9C1F-E138D2EF965FQ37734742-F38AFEE1-920C-49F2-8DFD-0FE4943BB585Q39060506-0365B170-3176-4770-AF0D-3F42802D2663Q46193918-127D1153-8AE2-4587-98B2-ED2FE83129EBQ46639074-2F9D07FD-3E0C-4D7A-A410-DC5500B92B7FQ47155189-8E12B14C-6DDF-47AD-8F65-BD798F64937DQ47666263-6C1C3D50-C957-4B0B-BECC-87F6B49B510EQ47690390-3CB51C84-E395-47DB-AC6D-90B65C645D8EQ48622660-DCD2A812-5860-401C-BC58-9F76F00AF9BF
P2860
Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@ast
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@en
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@nl
type
label
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@ast
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@en
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@nl
prefLabel
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@ast
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@en
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@nl
P2093
P2860
P50
P1433
P1476
Pharmacotherapy with fluoxetin ...... n mouse model of down syndrome
@en
P2093
Chiara Mangano
Laura Calzà
Renata Bartesaghi
P2860
P304
P356
10.1371/JOURNAL.PONE.0061689
P407
P577
2013-01-01T00:00:00Z